Previous 10 | Next 10 |
SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the closing of its previously announced registered direct offering of an aggregate of 5,454,548 shares of the Company’s ...
2024-04-01 12:57:59 ET More on Mid-day movers & stocks. Meta Materials total Q4 revenue up 55% y/y Meta Materials announces $1M civil penalty to settle SEC investigation Seeking Alpha’s Quant Rating on Connect Biopharma Historical earnings data for...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 93.4% to $0.117 on volume of 124,152,860 shares Jaguar Health Inc. (JAGX) fell 9.0% to $0.0818 on volume of 39,020,683 shares CXApp Inc. (CXAI) rose 82.9% to $4.48 on volume of 34,784,405 shares N...
2024-04-01 08:34:27 ET More on Biora Therapeutics Biora Therapeutics announces new capital investment Seeking Alpha’s Quant Rating on Biora Therapeutics Historical earnings data for Biora Therapeutics Financial information for Biora Therapeutics ...
2024-04-01 08:31:15 ET More on Pre-market losers & stocks. MicroStrategy Is A $1 Box Of Bitcoin Trading For $1.91 Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript MicroStrategy: A Bad Deal For Investors MicroStrategy among most squeezable ...
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has entered into definitive agreements for the purchase and sale of 5,454,548 shares of the Company’s common sto...
2024-03-26 19:54:08 ET Biora Therapeutics, Inc. (BIOR) Q4 2023 Results Conference Call March 26, 2024 04:30 PM ET Company Participants Chuck Pedala - LifeSci Advisors Adi Mohanty - CEO Ariella Kelman - Chief Medical Officer Eric d'Esparbes - CFO Confere...
2024-03-26 16:12:23 ET More on Biora Therapeutics Biora Therapeutics announces new capital investment Seeking Alpha’s Quant Rating on Biora Therapeutics Historical earnings data for Biora Therapeutics Financial information for Biora Therapeutics ...
All performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood Remainder of BT-600 clinical trial progressing well and on schedule...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...
News, Short Squeeze, Breakout and More Instantly...
Biora Therapeutics Inc. Company Name:
BIOR Stock Symbol:
NASDAQ Market:
Biora Therapeutics Inc. Website:
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of ...
Drug-device combination leverages Biora’s NaviCap ™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ab...